Article
Soluble epoxide hydrolase inhibitor, TPPU, attenuates progression of atherosclerotic lesions and vascular smooth muscle cell phenotypic switching.
Vascular pharmacology - 1 Aug 2022
Kim So Ah, Lee Ae Sin, Lee Han Bit, Hur Haeng Jeon, Lee Sang Hee, Sung Mi Jeong
Abstract excerpt
Atherosclerosis manifests as a chronic inflammation resulting from multiple interactions between circulating factors and various cell types in blood vessel walls. Growing evidence shows that phenotypic switching and proliferation of vascular smooth muscle cells (VSMCs) plays an important role in the progression of atherosclerosis. Soluble epoxide hydrolase (sEH)/epoxyeicosatrienoic acids are mediated by vascular...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
